ESR1 and breast cancer: ICEC0942 potently inhibited the growth of a panel of cancer cell lines and of ER+ breast cancer xenografts, and its favourable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) properties made ICEC0942 a promising clinical candidate [22].